Skip to main content

Table 1 Baseline demographics and characteristics

From: Safety and efficacy outcomes after intranasal administration of neural stem cells in cerebral palsy: a randomized phase 1/2 controlled trial

 

Treatment group (n, %)

Control group (n, %)

P value

Age, years

   

Mean ± SD

6.73 ± 2.12

5.72 ± 1.97

0.249

 > 6 years

8 (57%)

5 (50%)

 

 ≤ 6 years

6 (43%)

5 (50%)

 

Sex

  

1.000

Male

10 (71%)

7 (70%)

 

Female

4 (29%)

3 (30%)

 

Body weight (kg)

18.82 ± 4.13

22.10 ± 7.62

0.187

GMFCS

  

0.783

II

3(21%)

3(30%)

 

III

4(29%)

3(30%)

 

IV

5(36%)

4(40%)

 

V

2(14%)

1(10%)

 

MACS

  

0.162

II

5(36%)

6(60%)

 

III

3(21%)

1(10%)

 

IV

4(29%)

1(10%)

 

V

2(14%)

2(20%)

 
  1. SD: standard deviation; kg: kilogram; GMFCS: gross motor function classification system; MACS: manual ability classification system